These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 11577793)

  • 21. Nurses' perceptions of antiemetic effectiveness.
    Rhodes VA; McDaniel RW; Simms SG; Johnson M
    Oncol Nurs Forum; 1995 Sep; 22(8):1243-52. PubMed ID: 8532549
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 5-hydroxytryptamine type-3 receptor antagonists for chemotherapy-induced and radiotherapy-induced nausea and emesis: can we safely reduce the dose of administered agents?
    Aapro M; Blower P
    Cancer; 2005 Jul; 104(1):1-18. PubMed ID: 15929119
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Consensus regarding multiple day and rescue antiemetic therapy.
    De Mulder PH; Roila F; Kris MG; Marty MM
    Support Care Cancer; 1998 May; 6(3):248-52. PubMed ID: 9629878
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assuring the optimal use of serotonin antagonist antiemetics: the process for development and implementation of institutional antiemetic guidelines at Memorial Sloan-Kettering Cancer Center.
    Nolte MJ; Berkery R; Pizzo B; Baltzer L; Grossano D; Lucarelli CD; Kris MG
    J Clin Oncol; 1998 Feb; 16(2):771-8. PubMed ID: 9469369
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Chemotherapy induced emesis: pathophysiology and prevention].
    Mailliez A; Bonneterre J
    Bull Cancer; 2010 Feb; 97(2):233-43. PubMed ID: 20051348
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anticipatory nausea and vomiting in the era of 5-HT3 antiemetics.
    Morrow GR; Roscoe JA; Kirshner JJ; Hynes HE; Rosenbluth RJ
    Support Care Cancer; 1998 May; 6(3):244-7. PubMed ID: 9629877
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The use of antiemetics in cancer chemotherapy].
    Ghosn M; Droz JP
    J Med Liban; 1992; 40(2):106-7. PubMed ID: 1339878
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparison of oral ondansetron syrup or intravenous ondansetron loading dose regimens given in combination with dexamethasone for the prevention of nausea and emesis in pediatric and adolescent patients receiving moderately/highly emetogenic chemotherapy.
    White L; Daly SA; McKenna CJ; Zhestkova N; Leal C; Breatnach F; Smelhaus V; Hung IJ; Kowalczyk J; Ninane J; Mitchell T; Haigh C
    Pediatr Hematol Oncol; 2000 Sep; 17(6):445-55. PubMed ID: 10989464
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical efficacy of GG032X tablets, a new dosage form of ondansetron (fast dispersing tablet), on cisplatin-induced nausea and emesis].
    Ariyoshi Y; Nukariya N; Akasaka Y; Suminaga M; Ota J; Ikeda M; Taguchi T
    Gan To Kagaku Ryoho; 1997 Jun; 24(8):995-1011. PubMed ID: 9212810
    [TBL] [Abstract][Full Text] [Related]  

  • 30. State of the Art Antiemetic Therapy for Cancer Patients.
    Lau TK; Yip CH; Yeo W
    Curr Oncol Rep; 2016 Jan; 18(1):2. PubMed ID: 26694923
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacological management of chemotherapy-induced nausea and vomiting in children with cancer.
    Cefalo MG; Ruggiero A; Maurizi P; Attinà G; Arlotta A; Riccardi R
    J Chemother; 2009 Dec; 21(6):605-10. PubMed ID: 20071282
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
    Sorbe BG
    Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emesis as a complication of cancer chemotherapy: pathophysiology, importance, and treatment.
    Graves T
    Pharmacotherapy; 1992; 12(4):337-45. PubMed ID: 1387707
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Region-wide professional practice evaluation with regards to antiemetic prescription into chemotherapy-induced nausea and vomiting].
    Tavernier J; Jouannet-Romaszko M; Bertucat H; Marchiset N; Bahadoor M; Chevrier R
    Bull Cancer; 2016; 103(7-8):622-31. PubMed ID: 27178880
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiemetic activity of ondansetron in cancer patients receiving non-cisplatin chemotherapy.
    Fraschini G
    Semin Oncol; 1992 Aug; 19(4 Suppl 10):41-7. PubMed ID: 1387249
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acute and delayed nausea and emesis control in pediatric oncology patients.
    Holdsworth MT; Raisch DW; Frost J
    Cancer; 2006 Feb; 106(4):931-40. PubMed ID: 16404740
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiemetic strategies for high-dose chemoradiotherapy-induced nausea and vomiting.
    Spitzer TR; Grunberg SM; Dicato MA
    Support Care Cancer; 1998 May; 6(3):233-6. PubMed ID: 9629875
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemotherapy-induced nausea and vomiting: state of the art in 2006.
    Schwartzberg L
    J Support Oncol; 2006 Feb; 4(2 Suppl 1):3-8. PubMed ID: 16499138
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevention of acute emesis in cancer patients following high-dose cisplatin with the combination of oral dolasetron and dexamethasone.
    Kris MG; Pendergrass KB; Navari RM; Grote TH; Nelson AM; Thomas V; Ferguson BB; Allman DS; Pizzo BA; Baker TW; Fernando IJ; Chernoff SB
    J Clin Oncol; 1997 May; 15(5):2135-8. PubMed ID: 9164228
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The efficacy and cost effectiveness of new antiemetic guidelines.
    Engstrom C; Hernandez I; Haywood J; Lilenbaum R
    Oncol Nurs Forum; 1999 Oct; 26(9):1453-8. PubMed ID: 11064877
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.